Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Reclaiming Celexa Ahead Of Warner-Lambert Merger

Executive Summary

Forest is exercising its option to regain full marketing rights to the antidepressant Celexa (citalopram) under the change-in-control provisions of its co-promotion agreement with Warner-Lambert.

You may also be interested in...



Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations

Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.

Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations

Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.

Pfizer Lipitor Profitability Among Items In Dispute In Warner-Lambert Bid

The effect of the Lipitor co-promotion on Pfizer's earnings ranges from break-even to one quarter of profits, depending on which partner in the agreement is doing the accounting.

Related Content

UsernamePublicRestriction

Register

PS035197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel